Gazyva (obinutuzumab) — Medical Benefit Drug Policy for Active Lupus Nephritis
Customize your policy alerts
Sign up for sierra health and life Policy 2026D0140A alerts
Get alerted when Policy 2026D0140A changes without checking for updates manually.
Monitor payer policy activity
Medical benefit drug policy that governs coverage criteria for Gazyva (obinutuzumab) intravenous infusion for treatment of active lupus nephritis under Sierra Health and Life. Affects prescribers, infusion providers, and payers assessing prior authorization for this indication.
New Medical Benefit Drug Policy
Coverage Criteria for Gazyva (obinutuzumab)
Initial Therapy — Covered when ALL of the following are met for initial therapy
Covered when ALL of the following are met for initial therapy
All conditions required
Continuation Therapy — Covered when ALL of the following are met for continuation of therapy
Covered when ALL of the following are met for continuation of therapy
All conditions required
Use of Gazyva (obinutuzumab) in combination with Benlysta (belimumab) or Lupkynis (voclosporin) is explicitly excluded from covered indications under this policy. The coverage criteria for both initial and continuation therapy require that the patient is not receiving Gazyva in combination with belimumab or voclosporin as a condition of medical necessity and prior authorization.
Therapy will be considered not medically necessary if it does not meet all of the specified initial or continuation criteria. Examples that would lead to non‑coverage include failure to document a diagnosis of active lupus nephritis (or provider attestation that biopsy is contraindicated when required), lack of concurrent use of at least one standard non‑biologic SLE therapy (e.g., antimalarials, corticosteroids, or immunosuppressants), absence of required documentation of prior benefit for continuation, dosing not consistent with the US FDA label, or use of Gazyva in combination with excluded agents such as belimumab or voclosporin. Meeting all listed conditions is required for authorization.
Coding — HCPCS and Diagnosis Codes
| J9301 | Injection, obinutuzumab, 10 mg |
| M32.14 | Glomerular disease in systemic lupus erythematosus |
Provider Actions and Documentation Requirements
Prior authorization required for Gazyva for active lupus nephritis
Prior authorization is required for Gazyva (obinutuzumab) when used to treat active lupus nephritis. The request must document diagnosis of active lupus nephritis and either biopsy-proven disease or an attestation that biopsy is contraindicated; dosing must follow the US FDA label; and initial and continuation authorizations are limited to no more than 12 months. Prescriptions must be by or in consultation with a rheumatologist or nephrologist, and the patient must not be receiving Gazyva in combination with belimumab (Benlysta) or voclosporin (Lupkynis).
- Diagnosis of active lupus nephritis required
- Provider attestation that diagnosis is biopsy proven or biopsy is contraindicated
- Dosing per US FDA labeled dosing
- Initial/continuation authorization limited to ≤ 12 months
- Prescribed by or in consultation with a rheumatologist or nephrologist
- Not used in combination with Benlysta (belimumab) or Lupkynis (voclosporin)
Concurrent standard non-biologic therapy required
Coverage requires the patient to be currently receiving at least one standard-of-care, non-biologic treatment for active systemic lupus erythematosus (examples listed in the policy include antimalarials, corticosteroids, or immunosuppressants). This concurrent therapy requirement applies to both initial and continuation authorizations.
- Examples of acceptable concurrent therapies: antimalarials, corticosteroids, or immunosuppressants
- Concurrent therapy must be a non-biologic agent
Required clinical documentation
Providers must attest that the diagnosis is biopsy proven or document why biopsy is contraindicated, and must supply documentation of prior Gazyva use and positive clinical response when requesting continuation. Documentation must also confirm concurrent non-biologic SLE therapy and that Gazyva is not being combined with belimumab or voclosporin.
- Attestation that diagnosis is biopsy proven or biopsy is contraindicated
- For continuation: documentation of prior Gazyva administration and positive clinical response
- Evidence of concurrent standard non-biologic SLE therapy
- Confirmation Gazyva is not used with Benlysta or Lupkynis
Coverage contingent on meeting all listed criteria
Coverage will be denied if the patient does not meet all required criteria for initial or continuation therapy, including diagnosis requirements, concurrent non-biologic therapy, absence of excluded combinations, dosing per FDA label, and required prescriber specialty/consultation.
- Denial risk if biopsy-proven diagnosis or contraindication attestation is missing
- Denial risk if concurrent non-biologic SLE therapy is not documented
- Denial risk if Gazyva is prescribed in combination with belimumab or voclosporin
- Denial risk if dosing does not follow the FDA label or prescriber specialty requirement is not met
Background
Obinutuzumab (Gazyva) is a CD20‑directed monoclonal antibody that targets CD20 expressed on pre‑B and mature B lymphocytes and mediates B‑cell depletion through immune effector mechanisms, direct cell death, and complement activation.
Definitions and Trial Endpoints
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.